News headlines about Endocyte (NASDAQ:ECYT) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endocyte earned a news impact score of 0.03 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.7279004186912 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have impacted Accern’s scoring:
- What Does MACD Oscillator Analysis predict about Endocyte, Inc. (NASDAQ:ECYT)? (oracleexaminer.com)
- Price to Earnings Ratio under Review – Endocyte Inc (NASDAQ: ECYT) (stocksmarketcap.com)
- Endocyte, Inc. (ECYT) stock price is showing notable positive signal for long-term investors on basis of 200 day SMA at … (analystrecommendation.com)
- New Analyst Coverage Puts Spotlight on 5 Stocks (finance.yahoo.com)
- Endocyte (ECYT) Upgraded to “Buy” at ValuEngine (americanbankingnews.com)
ECYT has been the subject of several research analyst reports. ValuEngine downgraded Endocyte from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 21st. Zacks Investment Research downgraded Endocyte from a “hold” rating to a “sell” rating in a report on Thursday, February 1st. Cowen upgraded Endocyte from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 27th. BidaskClub upgraded Endocyte from a “sell” rating to a “hold” rating in a report on Saturday, March 3rd. Finally, Wells Fargo started coverage on Endocyte in a report on Friday, March 9th. They issued an “outperform” rating for the company. One analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $7.00.
Endocyte (NASDAQ:ECYT) last released its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The firm had revenue of $0.01 million during the quarter. Endocyte had a negative net margin of 78,662.86% and a negative return on equity of 40.33%. Endocyte’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.26) EPS. analysts predict that Endocyte will post -0.87 EPS for the current year.
In other Endocyte news, VP Christopher P. Leamon sold 5,036 shares of Endocyte stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $9.07, for a total value of $45,676.52. Following the transaction, the vice president now owns 143,470 shares in the company, valued at $1,301,272.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 14.86% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This report was published by BBNS and is the sole property of of BBNS. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://baseballnewssource.com/2018/04/05/endocyte-ecyt-receives-daily-coverage-optimism-score-of-0-03/2028513.html.
Endocyte Company Profile
Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.